HVR-1 heterogeneity during treatment with telaprevir with or without pegylated interferon alfa-2a

References

• Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975–82.
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346–55.
   PubMed Web of Science ®Google Scholar
• Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958–65.
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis interventional therapy group. N Engl J Med 1998;339:1485–92.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004;40:993–9.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666–72.
   PubMed Web of Science ®Google Scholar
• Lange CM, Sarrazin C, Zeuzem S. Review article: HCV - STAT-C era of therapy. Aliment Pharmacol Ther 2010;32:14–28.
   PubMed Web of Science ®Google Scholar
• Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010;138:447–62.
   PubMed Web of Science ®Google Scholar
• Lamarre D, Anderson PC, Bailey M, Beaulieu P, Bolger G, Bonneau P, An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003;426:186–9.
   PubMed Web of Science ®Google Scholar
• Reesink HW, Zeuzem S, Weegink CJ, Forestier N, Van Vliet A, Van De Wetering De Rooij J, Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 2006;131:997–1002.
   PubMed Web of Science ®Google Scholar
• Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Muh U, Welker M, Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007;132:1767–77.
   PubMed Web of Science ®Google Scholar
• Forestier N, Reesink HW, Weegink CJ, McNair L, Kieffer TL, Chu HM, Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 2007;46:640–8.
   PubMed Web of Science ®Google Scholar
• Hezode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009;360:1839–50.
   PubMed Web of Science ®Google Scholar
• Kieffer TL, Sarrazin C, Miller JS, Welker MW, Forestier N, Reesink HW, Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007;46:631–9.
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010;362:1292–303.
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009;360:1827–38.
   PubMed Web of Science ®Google Scholar
• Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment-naive patients: final results of phase 3 advance study. Hepatology 2010;52:427.
   Web of Science ®Google Scholar
• Abbate I, Lo Iacono O, Di Stefano R, Cappiello G, Girardi E, Longo R, HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated- or standard-interferon and ribavirin. J Hepatol 2004;40:831–6.
   PubMed Web of Science ®Google Scholar
• Gaud U, Langer B, Petropoulou T, Thomas HC, Karayiannis P. Changes in hypervariable region 1 of the envelope 2 glycoprotein of hepatitis C virus in children and adults with humoral immune defects. J Med Virol 2003;69:350–6.
   PubMed Web of Science ®Google Scholar
• Toyoda H, Fukuda Y, Koyama Y, Takamatsu J, Saito H, Hayakawa T. Effect of immunosuppression on composition of quasispecies population of hepatitis C virus in patients with chronic hepatitis C coinfected with human immunodeficiency virus. J Hepatol 1997;26:975–82.
   PubMed Web of Science ®Google Scholar
• Farci P, Strazzera R, Alter HJ, Farci S, Degioannis D, Coiana A, Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc Natl Acad Sci U S A 2002;99:3081–6.
   PubMed Web of Science ®Google Scholar
• Polyak SJ, McArdle S, Liu SL, Sullivan DG, Chung M, Hofgartner WT, Evolution of hepatitis C virus quasispecies in hypervariable region 1 and the putative interferon sensitivity-determining region during interferon therapy and natural infection. J Virol 1998;72:4288–96.
   PubMed Web of Science ®Google Scholar
• Colucci G, Ferguson J, Harkleroad C, Lee S, Romo D, Soviero S, Improved COBAS TaqMan hepatitis C virus test (Version 2.0) for use with the High Pure system: enhanced genotype inclusivity and performance characteristics in a multisite study. J Clin Microbiol 2007;45:3595–600.
   PubMed Web of Science ®Google Scholar
• Sarrazin C, Bruckner M, Herrmann E, Ruster B, Bruch K, Roth WK, Quasispecies heterogeneity of the carboxy-terminal part of the E2 gene including the PePHD and sensitivity of hepatitis C virus 1b isolates to antiviral therapy. Virology 2001;289:150–63.
   PubMed Web of Science ®Google Scholar
• Liang Y, Ishida H, Lenz O, Lin TI, Nyanguile O, Simmen K, Antiviral suppression vs restoration of RIG-I signaling by hepatitis C protease and polymerase inhibitors. Gastroenterology 2008;135:1710–18.
   PubMed Web of Science ®Google Scholar